FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 470 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Texas Baby Is Born With Almost No Skin On His Body,... April 24, 2019 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Breast Cancer Patient Devotes Her Time to Driving Others to Treatment March 15, 2021 New ESMO President 2029-2030 Elected June 3, 2026 Load more HOT NEWS FDA Approves Pralsetinib for RET-Altered Thyroid Cancers Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... Woman Donates 500 Care Packages To Breast Cancer Patients Can Having Solar Panels or Living Near a Solar Farm Increase...
